Procter & Gamble Health Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Milind Thatte

Chief executive officer

₹25.2m

Total compensation

CEO salary percentage	100.0%
CEO tenure	6.1yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Milind Thatte's remuneration changed compared to Procter & Gamble Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	₹25m	₹25m	₹2b
Mar 31 2023	n/a	n/a	₹2b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	₹39m	₹39m	₹2b
Mar 31 2022	n/a	n/a	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	₹32m	₹32m	₹2b
Mar 31 2021	n/a	n/a	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	₹17m	₹26m	₹2b
Mar 31 2020	n/a	n/a	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹1b
Mar 31 2019	n/a	n/a	₹1b
Dec 31 2018	₹20m	₹13m	₹1b

Compensation vs Market: Milind's total compensation ($USD302.08K) is about average for companies of similar size in the Indian market ($USD380.97K).

Compensation vs Earnings: Milind's compensation has been consistent with company performance over the past year.

CEO

Milind Thatte (54 yo)

6.1yrs

Tenure

₹25,184,000

Compensation

Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...

Board Members

Name	Position	Tenure	Compensation	Ownership
Milind Thatte	MD & Executive Director	6.1yrs	₹25.18m	no data
Lokesh Chandak	CFO, Finance Head & Executive Director	1.1yrs	₹27.76m	no data
Suresh Talwar	Non-Executive Independent Chairman of the Board	40.3yrs	₹2.38m	0.036% ₹ 28.4m
Subramanian Madhavan	Non-Executive Independent Director	2.5yrs	₹2.13m	no data
Rani Jadhav	Non-Executive Independent Director	9.3yrs	₹2.20m	no data
Aalok Agrawal	Non-Executive Director	4.9yrs	no data	no data
Seema Sambasivan	Non-Executive Director	1.1yrs	no data	no data

4.9yrs

Average Tenure

67yo

Average Age

Experienced Board: 500126's board of directors are considered experienced (4.9 years average tenure).

Procter & Gamble Health Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: ₹28.00 (vs ₹35.70 in 3Q 2023)

Procter & Gamble Health Limited to Report Q3, 2024 Results on May 02, 2024

Second quarter 2024 earnings released: EPS: ₹43.40 (vs ₹46.30 in 2Q 2023)

Procter & Gamble Health Limited Declares Special Dividend for the Financial Year 2023-24, Payable on or Before March 3, 2024

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited to Report Q1, 2024 Results on Nov 03, 2023

Procter & Gamble Health Limited Recommends Final Dividend,Payable Between November 28, 2023 to December 18, 2023

Full year 2023 earnings released: EPS: ₹138 (vs ₹116 in FY 2022)

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Procter & Gamble Health Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Third quarter 2023 earnings released: EPS: ₹35.70 (vs ₹30.80 in 3Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Procter & Gamble Health Limited Recommends an Interim Dividend for the Financial Year 2022-23, Payable on or Before March 05, 2023

Second quarter 2023 earnings released: EPS: ₹46.30 (vs ₹27.00 in 2Q 2022)

Less than half of directors are independent

First quarter 2023 earnings released: EPS: ₹38.30 (vs ₹33.40 in 1Q 2022)

Upcoming dividend of ₹11.50 per share

Procter & Gamble Health Limited to Report Q3, 2022 Results on Nov 09, 2022

Procter & Gamble Health Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: EPS: ₹116 (vs ₹107 in FY 2021)

Procter & Gamble Health Limited Recommends Final Dividend for the Financial Year Ended June 30, 2022, Payable Between November 28, 2022 to December 18, 2022

Procter & Gamble Health Limited to Report Fiscal Year 2022 Results on Aug 29, 2022

Procter & Gamble Health Limited Recommends Interim Dividend for the Financial Year 2021-22, payable on or before May 31, 2022

Third quarter 2022 earnings released: EPS: ₹30.80 (vs ₹9.50 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹130 per share

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Non-Executive Director Sujay Wasan has left the company

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Procter & Gamble Health Limited Recommends One-Time Special Dividend for the Financial Year Ended June 30, 2021

Company Secretary & Compliance Officer Preeti Bishnoi has left the company

New 90-day low: ₹6,562

Second quarter 2021 earnings released: EPS ₹40.90 (vs ₹23.02 in 2Q 2020)

New 90-day high: ₹7,315

New 90-day high: ₹7,107

New 90-day high: ₹7,030

First quarter 2021 earnings released: EPS ₹35.70

New 90-day high: ₹5,682

Full year earnings released - EPS ₹99.98

New 90-day high - ₹5,251

Procter & Gamble Health Limited to Report Q2, 2020 Results on Sep 15, 2020

New 90-day high - ₹4,879

New 90-day high - ₹4,402

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age